2-deoxy-D-glucose in a human rhinovirus challenge model: A randomized, double-blind placebo-controlled phase 2a clinical trial - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Phase 2a Randomized, Double-Blind, Placebo-Controlled Trial of 2-Deoxy-D-Glucose in a Human Rhinovirus Challenge Model

  • By

  • Victor M. Cnossen

  • Salma Assil

  • Marieke L. de Kam

  • Meta Roestenberg

  • Anna-Dorothea Gorki

  • Ronald B. Turner

  • Guido A. Gualdoni

  • Ingrid M.C. Kamerling

  • October 27, 2026

Share

  • 1

    This randomized, double-blind, placebo-controlled phase 2a trial evaluated intranasal 2-deoxy-D-glucose (2-DG) in 64 healthy adults challenged with rhinovirus 39 (RV39).

  • 2

    Participants received 2-DG at 14 mg per dose or placebo four times daily, from 1 day before inoculation through 5 days afterward, with two doses on the first and final days.

  • 3

    In the primary per-protocol analysis, rhinovirus-associated illness occurred in 16/27 participants (59.3%) receiving 2-DG and 17/29 (58.6%) receiving placebo.

  • 4

    Laboratory-confirmed infection rates, viral loads, and symptom scores did not differ significantly. The trial stopped after its planned interim analysis because the recalculated sample size was considered infeasible.

  • 5

    Treatment-emergent adverse events affected 40.6% of participants receiving 2-DG and 50.0% receiving placebo. No severe or serious adverse events occurred, and none prompted treatment discontinuation or modification.

Original Source(s)

2-deoxy-D-glucose in a human rhinovirus challenge model: A randomized, double-blind placebo-controlled phase 2a clinical trial

  • by Victor M. Cnossen, Salma Assil, Marieke L. de Kam, Meta Roestenberg, Anna-Dorothea Gorki, Ronald B. Turner, Guido A. Gualdoni, Ingrid M.C. Kamerling

  • October 27, 2026

Related Content

Shared Clinical Decision-Making for Rotavirus Vaccination and Future Health Care Use in Infants

Much of the excess mortality in immunocompromised patients with viral severe acute respiratory infection occurs after ICU discharge

What do the findings of compartmentalised sub-phenotypes in lungs of patients with pneumonia mean for critical care?